周二盘中，徕博科（LH）股价大幅下跌5.68%，引发市场关注。这一显著跌幅似乎与公司最新发布的业务展望直接相关。
根据公司高管在最新电话会议上的表态，徕博科预计2025年早期药物开发业务将实现低个位数增长，这一预期较此前的中个位数增长有所下调。这一消息无疑打击了投资者信心，导致股价应声下跌。
作为一家领先的生命科学公司，徕博科的早期药物开发业务是其核心收入来源之一。增长预期的下调可能暗示该业务segment面临的挑战增加，或整体市场环境趋于保守。分析人士指出，这一调整可能会影响投资者对公司未来盈利能力的判断，进而导致股价承压。投资者将密切关注公司后续的业务发展和管理层的应对策略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.